title: Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement.
abstract: OBJECTIVE
  The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components of follow-up care, including health promotion, prostate cancer surveillance, screening for new cancers, long-term and late functional effects of the disease and its treatment, psychosocial issues, and coordination of care between the survivor's primary care physician and prostate cancer specialist.
  
  
  METHODS
  The American Cancer Society (ACS) Prostate Cancer Survivorship Care Guidelines were reviewed for developmental rigor by methodologists. The American Society of Clinical Oncology (ASCO) Endorsement Panel reviewed the content and recommendations, offering modifications and/or qualifying statements when deemed necessary.
  
  
  RESULTS
  The ASCO Endorsement Panel determined that the recommendations from the 2014 ACS Prostate Cancer Survivorship Care Guidelines are clear, thorough, and relevant, despite the limited availability of high-quality evidence to support many of the recommendations. ASCO endorses the ACS Prostate Cancer Survivorship Care Guidelines, with a number of qualifying statements and modifications.
  
  
  CONCLUSIONS
  Assess information needs related to prostate cancer, prostate cancer treatment, adverse effects, and other health concerns and provide or refer survivors to appropriate resources. Measure prostate-specific antigen (PSA) level every 6 to 12 months for the first 5 years and then annually, considering more frequent evaluation in men at high risk for recurrence and in candidates for salvage therapy. Refer survivors with elevated or increasing PSA levels back to their primary treating physician for evaluation and management. Adhere to ACS guidelines for the early detection of cancer. Assess and manage physical and psychosocial effects of prostate cancer and its treatment. Annually assess for the presence of long-term or late effects of prostate cancer and its treatment.
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Matthew J
authors: MJ
authors: Resnick
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Christina
authors: C
authors: Lacchetti
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Jonathan
authors: J
authors: Bergman
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Ralph J
authors: RJ
authors: Hauke
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Karen E
authors: KE
authors: Hoffman
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Terrence M
authors: TM
authors: Kungel
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: Alicia K
authors: AK
authors: Morgans
authors: Matthew J. Resnick and David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Affairs Health Care System; Alicia K. Morgans, Vanderbilt-Ingram Cancer Center, Nashville, TN; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Jonathan Bergman, David Geffen School of Medicine, University of California, Los Angeles and Veterans Health Administration of Greater Los Angeles, Los Angeles, CA; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Karen E. Hoffman, University of Texas MD Anderson Cancer Center, Houston, TX; and Terrence M. Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME.
authors: David F
authors: DF
authors: Penson
mesh_terms: D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D017410:Practice Guidelines as Topic; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D012955:Societies, Medical; D015996:Survival Rate; D014481:United States